類風濕關(guān)節(jié)炎(RA)是一種自身免疫性疾病,，將導致炎癥和關(guān)節(jié)破壞。盡管抗風濕藥物具有一定的廣譜性,，但是由于類風濕關(guān)節(jié)炎是一種存在多種發(fā)病原因和機制的異質(zhì)性疾病,，超過30%的患者的類風濕關(guān)節(jié)炎并沒有得到很好的控制。
2015年4月在《Trends in pharmacological sciences》(藥理學趨勢)雜志發(fā)表了一篇文章,，提出兩種新的風濕病治療途徑,，涉及兩種新的治療靶點：Janus激酶(JAK)通路和T helper-17(Th17)通路[包括白細胞介素IL17,，IL-21，IL-22,，和粒細胞-巨噬細胞集落刺激因子(GM-CSF)],。文章也對目前能夠通過這些途徑治療的潛在生物制劑和小分子抑制劑進行了綜述。文章指出聯(lián)合用藥,，并篩選相關(guān)生物標志物,，將有助于實現(xiàn)RA患者的有效個性化治療。
摘要原文：
Trends Pharmacol Sci. 2015 Apr;36(4):189-195. doi: 10.1016/j.tips.2015.02.001. Epub 2015 Feb 27.
Novel therapeutic targets in rheumatoid arthritis.
Koenders MI1, van den Berg WB2.
Author information
Abstract
Rheumatoid arthritis (RA) is an autoimmune disease that leads to inflammation and destruction of synovial joints. Despite the broad spectrum of antirheumatic drugs, this heterogeneous disease is still not well controlled in up to 30% of patients. Here, we discuss two pathways that are regarded as interesting novel therapeutic targets in the field of rheumatology: the Janus kinase (JAK) pathway and the T helper-17 (Th17) pathway [including interleukin (IL)-17, IL-21, IL-22, and granulocyte-macrophage colony-stimulating factor (GM-CSF)]. We also review the therapy potential of biologicals and small-molecule inhibitors blocking these pathways. Advances in combination therapy in addition to progress in biomarker screening will help us to further achieve effective and personalized healthcare for patients with RA.
